| Larimar Therapeutics, Inc.announced 24 Feb 2026 |
Dose first patient in global confirmatory Phase 3 study |
Not met30 Jun 2026 |
| Larimar Therapeutics, Inc.announced 29 Sep 2025 |
Conduct process performance qualification on commercial scale drug substance |
Not met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 29 Sep 2025 |
Implement the new dosing regimen in the ongoing open label study |
Met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 14 Aug 2025 |
Provide initial data from the 50 mg dose open label study and adolescent PK run-in study |
Met30 Sep 2025 |
| Larimar Therapeutics, Inc.announced 14 Aug 2025 |
Release open label data from nomlabofusp study |
Met30 Sep 2025 |
| Larimar Therapeutics, Inc.announced 14 Aug 2025 |
Initiate patient recruitment for the global Phase 3 study |
Not met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 23 Jun 2025 |
Introduce lyophilized dosage form of nomlabofusp |
Met · disputed30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 23 Jun 2025 |
Launch nomlabofusp in the U.S |
Open31 Mar 2027 |
| Larimar Therapeutics, Inc.announced 5 May 2025 |
Report data from adolescent cohort of PK run-in study |
Met30 Sep 2025 |
| Larimar Therapeutics, Inc.announced 24 Mar 2025 |
Complete dosing of adolescent cohort in PK run-in study |
Met31 Mar 2025 |
| Larimar Therapeutics, Inc.announced 24 Mar 2025 |
Introduce lyophilized product into clinical development program |
Met30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 24 Mar 2025 |
Introduce lyophilized dosage form into clinical studies |
Met30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 24 Mar 2025 |
Report topline OLE and PK run-in study data |
Met30 Sep 2025 |
| Larimar Therapeutics, Inc.announced 16 Dec 2024 |
Initiate dosing in pediatric PK run-in study for adolescents |
Met31 Mar 2025 |
| Larimar Therapeutics, Inc.announced 16 Dec 2024 |
Report long-term 50 mg nomlabofusp data |
Late30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 16 Dec 2024 |
Enroll children in pediatric PK run-in study |
Withdrawn30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 16 Dec 2024 |
Report initial data from 50 mg dose in long-term OLE study |
Not met30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 7 Aug 2024 |
Initiate a pharmacokinetic run-in study in adolescents |
Late31 Dec 2024 |
| Larimar Therapeutics, Inc.announced 7 Aug 2024 |
Initiate global double-blind placebo-controlled registration/confirmatory study |
Not met30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 7 Aug 2024 |
Initiate a global confirmatory study |
Not met30 Jun 2025 |
| Larimar Therapeutics, Inc.announced 7 Aug 2024 |
File a Biologics License Application |
Not met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 10 Jun 2024 |
Report interim data from the OLE study |
Met31 Dec 2024 |
| Larimar Therapeutics, Inc.announced 10 Jun 2024 |
Submit a BLA for nomlabofusp |
Not met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 12 Feb 2024 |
Submit a Biologics License Application for nomlabofusp |
Not met31 Dec 2025 |
| Larimar Therapeutics, Inc.announced 10 Aug 2023 |
Initiate open-label extension trial with 25 mg daily dosing |
Met31 Mar 2024 |
| Larimar Therapeutics, Inc.announced 25 Jul 2023 |
Initiate 50 mg cohort in Phase 2 dose exploration trial |
Met30 Sep 2023 |
| Larimar Therapeutics, Inc.announced 25 Jul 2023 |
Report interim data from the open label extension trial |
Met31 Dec 2024 |
| Larimar Therapeutics, Inc.announced 10 Nov 2022 |
Provide an update on the Phase 2 dose exploration study |
Met30 Jun 2023 |
| Larimar Therapeutics, Inc.announced 10 Nov 2022 |
Provide an update on the Phase 2 trial |
Met30 Jun 2023 |
| Larimar Therapeutics, Inc.announced 14 Sep 2022 |
Begin the Phase 2 dose exploration trial of CTI-1601 |
Met31 Dec 2022 |
| Larimar Therapeutics, Inc.announced 14 Sep 2022 |
Initiate Phase 2 dose exploration study in Friedreich's ataxia patients |
Met31 Dec 2022 |
| Larimar Therapeutics, Inc.announced 14 Sep 2022 |
Report top-line data from the Phase 2 trial |
Late31 Dec 2023 |
| Larimar Therapeutics, Inc.announced 11 Aug 2022 |
Submit a complete response to the CTI-1601 clinical hold |
Met30 Sep 2022 |
| Larimar Therapeutics, Inc.announced 4 Mar 2021 |
Report topline data from the placebo-controlled SAD and MAD Phase 1 trials of CTI-1601 |
Met30 Jun 2021 |
| Larimar Therapeutics, Inc.announced 4 Mar 2021 |
Initiate the JIVE open-label extension trial and a pediatric MAD trial in FA patients |
Late31 Dec 2021 |